A proof-of-concept study supports the safety and efficacy of rezpegaldesleukin vs placebo for treating severe-to-very-severe ...
But the CMS’s cancer-focused alternative payment model’s losses “mask successes” that should serve as lessons, experts say.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results